Finoriq research workspace
Aura Biosciences, Inc. (AURA) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Aura Biosciences, Inc. (AURA).
Company Snapshot
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Company
- Aura Biosciences, Inc. (AURA)
- Ticker
- AURA
- Market Cap
- $704.4M
- Latest Price
- $6.81
- Industry
- Biotech & Pharma
Aura Biosciences, Inc. (AURA) Recent Insider Transactions
Recent market insider transaction records indexed for Aura Biosciences, Inc. (AURA).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Kilroy ConorSee Remarks | S | Disposed | -$82,401 | 2026-04-16 |
| Kilroy ConorSee Remarks | S | Disposed | -$60,999 | 2026-02-17 |
| Plavsic MarkChief Technology Officer | S | Disposed | -$80,245 | 2026-02-17 |
| Hopkins Janet JillChief Medical Officer | S | Disposed | -$103,229 | 2026-02-17 |
| Elazzouzi AmySenior Vice President, Finance | S | Disposed | -$43,258 | 2026-02-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.